Corporate venture groups fund $17mm Series A for ArmaGen
Executive Summary
Boehringer Ingelheim Venture Fund (BIVF) was the lead investor in a $17mm Series A financing for ArmaGen Technologies Inc. (recombinant fusion proteins targeting the blood-brain barrier (BBB) for brain and spinal cord diseases). Shire PLC, Takeda Ventures, and Mitsui & Co. Global Investment also participated. Representatives from BIVF and Shire have joined the company’s board.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Drug Delivery
- Macromolecule
- Site Specific
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice